View in EDS HTML Full Text PDF Full Text

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Saved in:
Bibliographic Details
Title: Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Authors: Bahlis, Nizar J.1 (AUTHOR) nbahlis@ucalgary.ca, Zonder, Jeffrey2 (AUTHOR), Karlin, Lionel3 (AUTHOR), Plesner, Torben4 (AUTHOR), Paris, Laura5 (AUTHOR), Wrobel, Tomasz6 (AUTHOR), Hungria, Vania7 (AUTHOR), Besemer, Britta8 (AUTHOR), Crusoe, Edvan9 (AUTHOR), Silkjaer, Trine10 (AUTHOR), Perrot, Aurore11 (AUTHOR), Moreau, Philippe12 (AUTHOR), Wu, Ka Lung13 (AUTHOR), Delimpasi, Sosana14 (AUTHOR), Dimopoulos, Meletios A.15,16 (AUTHOR), Levin, Mark-David17 (AUTHOR), Mangiacavalli, Silvia18 (AUTHOR), Nnane, Ivo19 (AUTHOR), Kim, Yu Jin20 (AUTHOR), Krevvata, Maria19 (AUTHOR)
Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2685-2696. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2025.2561117